Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

In this trial in patients with relapsed CLL, progression-free survival at 2 years was 78% with zanubrutinib and 66% with ibrutinib. Infections were common with both; cardiac events were less frequent with zanubrutinib.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 388; no. 4; pp. 319 - 332
Main Authors Brown, Jennifer R., Eichhorst, Barbara, Hillmen, Peter, Jurczak, Wojciech, Kaźmierczak, Maciej, Lamanna, Nicole, O’Brien, Susan M., Tam, Constantine S., Qiu, Lugui, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda, Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte A., Salmi, Tommi, Wang, Megan-Der-Yu, Fu, Lina, Li, Jessica, Wu, Kenneth, Cohen, Aileen, Shadman, Mazyar
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 26.01.2023
Subjects
Adverse events
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Bruton's tyrosine kinase
Cardiac arrhythmia
Chronic lymphocytic leukemia
Death
Disease Progression
Drug dosages
FDA approval
Gene deletion
Heart
Heart Diseases - chemically induced
Hematology
Humans
Hypotheses
Inhibitor drugs
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Lymphoma
Medicin och hälsovetenskap
Oncology
Protein-tyrosine kinase
Statistical analysis
Survival
Targeted cancer therapy
Treatments in Oncology
Online AccessGet full text

Cover

More Information
Summary:In this trial in patients with relapsed CLL, progression-free survival at 2 years was 78% with zanubrutinib and 66% with ibrutinib. Infections were common with both; cardiac events were less frequent with zanubrutinib.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2211582